MedTrace Logo

The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS

NCT04651855 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-03

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety of intrathecal administration of Wharton's Jelly Mesenchymal Stem Cells (WJMSC) and the impact on the immune system of patients with Amyotrophic Lateral Sclerosis.

Conditions

Interventions

DRUG

Mesenchymal stem cells isolated from Wharton's jelly

Intrathecal administration of mesenchymal stem cells

Sponsors & Collaborators

  • National Center for Research and Development, Poland

    collaborator OTHER

  • Polski Bank Komorek Macierzystych JSC (PBKM)

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2022-03-08
Completion
2023-04-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04651855 on ClinicalTrials.gov